PAIN
Volume 149, Issue 1 , Pages 33-49 , April 2010

Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain

  • BaoXi Gao

      Affiliations

    • Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks CA 91320, USA
    • These authors contributed equally to this work.
    • ,
  • Markus Hierl

      Affiliations

    • Department of Neuroscience, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • Department of Lead Discovery, Amgen, Inc., Josef-Engert-St. 11, D-93053 Regensburg, Germany
    • These authors contributed equally to this work.
    • ,
  • Kristie Clarkin

      Affiliations

    • Department of Protein Sciences, Amgen, Inc., One Amgen Center Drive, Thousand Oaks CA 91320, USA
    • ,
  • Todd Juan

      Affiliations

    • Department of Protein Sciences, Amgen, Inc., One Amgen Center Drive, Thousand Oaks CA 91320, USA
    • ,
  • Hung Nguyen

      Affiliations

    • Department of Protein Sciences, Amgen, Inc., One Amgen Center Drive, Thousand Oaks CA 91320, USA
    • ,
  • Marissa van der Valk

      Affiliations

    • Department of Protein Sciences, Amgen, Inc., One Amgen Center Drive, Thousand Oaks CA 91320, USA
    • ,
  • Hong Deng

      Affiliations

    • Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks CA 91320, USA
    • ,
  • Wenhong Guo

      Affiliations

    • Department of Neuroscience, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • ,
  • Sonya G. Lehto

      Affiliations

    • Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks CA 91320, USA
    • ,
  • David Matson

      Affiliations

    • Department of Neuroscience, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • ,
  • Jeff S. McDermott

      Affiliations

    • Department of Neuroscience, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks CA 91320, USA
    • ,
  • Johannes Knop

      Affiliations

    • Department of Lead Discovery, Amgen, Inc., Josef-Engert-St. 11, D-93053 Regensburg, Germany
    • ,
  • Kevin Gaida

      Affiliations

    • Department of Inflammation, Amgen, Inc., One Amgen Center Drive, Thousand Oaks CA 91320, USA
    • ,
  • Lei Cao

      Affiliations

    • Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • ,
  • Dan Waldon

      Affiliations

    • Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • ,
  • Brian K. Albrecht

      Affiliations

    • Department of Chemistry Research and Development, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • ,
  • Alessandro A. Boezio

      Affiliations

    • Department of Chemistry Research and Development, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • ,
  • Katrina W. Copeland

      Affiliations

    • Department of Chemistry Research and Development, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • ,
  • Jean-Christophe Harmange

      Affiliations

    • Department of Chemistry Research and Development, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • ,
  • Stephanie K. Springer

      Affiliations

    • Department of Chemistry Research and Development, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • ,
  • Annika B. Malmberg

      Affiliations

    • Department of Neuroscience, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • ,
  • Stefan I. McDonough

      Affiliations

    • Department of Neuroscience, Amgen, Inc., 360 Binney Street, Cambridge MA 02142, USA
    • Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks CA 91320, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 617 444 5580; fax: +1 617 494 1075.

Received 25 August 2009 ,Revised 16 December 2009 ,Accepted 11 January 2010.

References 

  1. Aceto MD, Bagley RS, Dewey WL, Fu TC, Martin BR. The spinal cord as a major site for the antinociceptive action of nicotine in the rat. Neuropharmacology. 1986;25:1031–1036
  2. Albrecht BK, Berry V, Boezio AA, Cao L, Clarkin K, Guo W, et al. Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiators. Bioorg Med Chem Lett. 2008;18:5209–5212
  3. Arneric SP, Holladay M, Williams M. Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem Pharmacol. 2007;74:1092–1101
  4. Aznavour N, Mechawar N, Watkins KC, Descarries L. Fine structural features of the acetylcholine innervation in the developing neostriatum of rat. J Comp Neurol. 2003;460:280–291[erratum appears in J Comp Neurol 2003 Oct 27;465:620]
  5. Badio B, Daly JW. Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol. 1994;45:563–569
  6. Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ, et al. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J Pharmacol Exp Ther. 1998;285:787–794
  7. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, et al. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science. 1998;279:77–81
  8. Bannon AW, Decker MW, Kim DJ, Campbell JE, Arneric SP. ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain. Brain Res. 1998;801:158–163
  9. Bauer CS, Nieto-Rostro M, Rahman W, Tran-Van-Minh A, Ferron L, Douglas L, et al. The increased trafficking of the calcium channel subunit a2d–1 to presynaptic terminals in neuropathic pain is inhibited by the a2d–1 ligand pregabalin. J Neurosci. 2009;29:4076–4088
  10. Bee LA, Dickenson AH. Rostral ventromedial medulla control of spinal sensory processing in normal and pathophysiological states. Neuroscience. 2007;147:786–793
  11. Bitner RS, Nikkel AL, Curzon P, Arneric SP, Bannon AW, Decker MW. Role of the nucleus raphe magnus in antinociception produced by ABT-594: immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons. J Neurosci. 1998;18:5426–5432
  12. Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, et al. SSR180711, a novel selective α7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology. 2007;32:1–16
  13. Briggs CA, Gubbins EJ, Putman CB, Thimmapaya R, Meyer MD, Surowy CS. High- and low-sensitivity subforms of α4β2 and α3β2 nAChRs. J Mol Neurosci. 2006;30:11–12
  14. Broad LM, Zwart R, Pearson KH, Lee M, Wallace L, McPhie GI, et al. Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther. 2006;318:1108–1117
  15. Bunnelle WH, Daanen JF, Ryther KB, Schrimpf MR, Dart MJ, Gelain A, et al. Structure–activity studies and analgesic efficacy of N-(3-pyridinyl)-bridged bicyclic diamines, exceptionally potent agonists at nicotinic acetylcholine receptors. J Med Chem. 2007;50:3627–3644
  16. Bunnelle WH, Dart MJ, Schrimpf MR. Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity. Curr Top Med Chem. 2004;4:299–334
  17. Carroll FI, Brieaddy LE, Navarro HA, Damaj MI, Martin BR. Synthesis and pharmacological characterization of exo-2-(2′-chloro-5-pyridinyl)-7-(endo and exo)-aminobicyclo[2.2.1]heptanes as novel epibatidine analogues. J Med Chem. 2005;48:7491–7495
  18. Castillo M, Mulet J, Gutierrez LM, Ortiz JA, Castelan F, Gerber S, et al. Dual role of the RIC-3 protein in trafficking of serotonin and nicotinic acetylcholine receptors. J Biol Chem. 2005;280:27062–27068
  19. Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, Johnson EC. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4 and hα7 expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1997;280:346–356
  20. Chavez-Noriega LE, Gillespie A, Stauderman KA, Crona JH, Claeps BO, Elliott KJ, et al. Characterization of the recombinant human neuronal nicotinic acetylcholine receptors α3β2 and α4β2 stably expressed in HEK293 cells. Neuropharmacology. 2000;39:2543–2560
  21. Chen D, Patrick JW. The α-bungarotoxin-binding nicotinic acetylcholine receptor from rat brain contains only the α7 subunit. J Biol Chem. 1997;272:24024–24029
  22. Chen Y, Sharples TJ, Phillips KG, Benedetti G, Broad LM, Zwart R, et al. The nicotinic α4β2 receptor selective agonist, TC-2559, increases dopamine neuronal activity in the ventral tegmental area of rat midbrain slices. Neuropharmacology. 2003;45:334–344
  23. Chimbira W, Sweeney BP. The effect of smoking on postoperative nausea and vomiting. Anaesthesia. 2000;55:540–544
  24. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474–3477
  25. Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, et al. SSR591813, a novel selective and partial α4β2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther. 2003;306:407–420
  26. Conroy WG, Berg DK. Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions. J Biol Chem. 1995;270:4424–4431
  27. Craig PJ, Bose S, Zwart R, Beattie RE, Folly EA, Johnson LR, et al. Stable expression and characterisation of a human α7 nicotinic subunit chimera: a tool for functional high-throughput screening. Eur J Pharmacol. 2004;502:31–40
  28. Cucchiaro G, Chaijale N, Commons KG. The dorsal raphe nucleus as a site of action of the antinociceptive and behavioral effects of the α4 nicotinic receptor agonist epibatidine. J Pharmacol Exp Ther. 2005;313:389–394
  29. D’Mello R, Dickenson AH. Spinal cord mechanisms of pain. Br J Anaesth. 2008;101:8–16
  30. Damaj MI, Fonck C, Marks MJ, Deshpande P, Labarca C, Lester HA, et al. Genetic approaches identify differential roles for α4β2∗ nicotinic receptors in acute models of antinociception in mice. J Pharmacol Exp Ther. 2007;321:1161–1169
  31. Damaj MI, Meyer EM, Martin BR. The antinociceptive effects of α7 nicotinic agonists in an acute pain model. Neuropharmacology. 2000;39:2785–2791
  32. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol. 2007;47:699–729
  33. Davila-Garcia MI, Musachio JL, Perry DC, Xiao Y, Horti A, London ED, et al. [125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. J Pharmacol Exp Ther. 1997;282:445–451
  34. Decker MW, Meyer MD, Sullivan JP. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001;10:1819–1830
  35. Decker MW, Rueter LE, Bitner RS. Nicotinic acetylcholine receptor agonists: a potential new class of analgesics. Curr Top Med Chem. 2004;4:369–384
  36. Descarries L. The hypothesis of an ambient level of acetylcholine in the central nervous system. J Physiol [Paris]. 1998;92:215–220
  37. Descarries L, Gisiger V, Steriade M. Diffuse transmission by acetylcholine in the CNS. Prog Neurobiol. 1997;53:603–625
  38. Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, et al. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization. J Pharmacol Exp Ther. 1998;285:777–786
  39. Drenan RM, Nashmi R, Imoukhuede P, Just H, McKinney S, Lester HA. Subcellular trafficking, pentameric assembly, and subunit stoichiometry of neuronal nicotinic acetylcholine receptors containing fluorescently labeled α6 and β3 subunits. Mol Pharmacol. 2008;73:27–41
  40. Drisdel RC, Green WN. Neuronal α-bungarotoxin receptors are α7 subunit homomers. J Neurosci. 2000;20:133–139
  41. Faessel HM, Smith BJ, Gibbs MA, Gobey JS, Clark DJ, Burstein AH. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol. 2006;46:991–998
  42. Farber L, Stratz T, Bruckle W, Spath M, Pongratz D, Lautenschlager J, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia – a highly selective and competitive 5-HT3 receptor antagonist. Scand J Rheumatol Suppl. 2000;113:49–54
  43. Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, et al. The selective nicotinic acetylcholine receptor α7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology. 2009;56:254–263
  44. Fitch RW, Xiao Y, Kellar KJ, Daly JW. Membrane potential fluorescence: a rapid and highly sensitive assay for nicotinic receptor channel function. Proc Natl Acad Sci USA. 2003;100:4909–4914
  45. Flores CM. The promise and pitfalls of a nicotinic cholinergic approach to pain management. Pain. 2000;88:1–6
  46. Flores CM, DeCamp RM, Kilo S, Rogers SW, Hargreaves KM. Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: demonstration of α3β4, a novel subtype in the mammalian nervous system. J Neurosci. 1996;16:7892–7901
  47. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol. 1992;41:31–37
  48. Fucile S, Barabino B, Palma E, Grassi F, Limatola C, Mileo AM, et al. A5 subunit forms functional α3β4α5 nAChRs in transfected human cells. Neuroreport. 1997;8:2433–2436
  49. Gao BX, Ziskind-Conhaim L. Development of glycine- and GABA-gated currents in rat spinal motoneurons. J Neurophysiol. 1995;74:113–121
  50. Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, et al. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev. 2004;10:147–166
  51. Genzen JR, McGehee DS. Short- and long-term enhancement of excitatory transmission in the spinal cord dorsal horn by nicotinic acetylcholine receptors. Proc Natl Acad Sci USA. 2003;100:6807–6812
  52. Genzen JR, McGehee DS. Nicotinic modulation of GABAergic synaptic transmission in the spinal cord dorsal horn. Brain Res. 2005;1031:229–237
  53. Gerzanich V, Wang F, Kuryatov A, Lindstrom J. A5 Subunit alters desensitization, pharmacology, Ca2+ permeability and Ca2+ modulation of human neuronal α3 nicotinic receptors. J Pharmacol Exp Ther. 1998;286:311–320
  54. Girod R, Crabtree G, Ernstrom G, Ramirez-Latorre J, McGehee D, Turner J, et al. Heteromeric complexes of α5 and/or α7 subunits. Effects of calcium and potential role in nicotine-induced presynaptic facilitation. Ann NY Acad Sci. 1999;868:578–590
  55. Grosman C, Auerbach A. Kinetic, mechanistic, and structural aspects of unliganded gating of acetylcholine receptor channels: a single-channel study of second transmembrane segment 12′ mutants. J Gen Physiol. 2000;115:621–635
  56. Gurun MS, Parker R, Eisenach JC, Vincler M. The effect of peripherally administered CDP-choline in an acute inflammatory pain model: the role of α7 nicotinic acetylcholine receptor. Anesth Analg. 2009;108:1680–1687
  57. Habib AS, White WD, El Gasim MA, Saleh G, Polascik TJ, Moul JW, et al. Transdermal nicotine for analgesia after radical retropubic prostatectomy. Anesth Analg. 2008;107:999–1004
  58. Hong LE, Wonodi I, Lewis J, Thaker GK. Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients. Neuropsychopharmacology. 2008;33:2167–2174
  59. Horenstein NA, McCormack TJ, Stokes C, Ren K, Papke RL. Reversal of agonist selectivity by mutations of conserved amino acids in the binding site of nicotinic acetylcholine receptors. J Biol Chem. 2007;282:5899–5909
  60. Available from: http://www.neurosearch.com/Default.aspx?ID=16&M=News&PID=12&NewsID=15702.
  61. Available from: http://www.targacept.com/wt/page/pr_1196665010.
  62. Hurst RS, Hajos M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, et al. A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci. 2005;25:4396–4405
  63. Jackson MB. Toward a mechanism of gating of chemically activated channels. Adv Neurol. 1986;44:171–189
  64. Khan I, Osaka H, Stanislaus S, Calvo RM, Deerinck T, Yaksh TL, et al. Nicotinic acetylcholine receptor distribution in relation to spinal neurotransmission pathways. J Comp Neurol. 2003;467:44–59
  65. Khan IM, Stanislaus S, Zhang L, Taylor P, Yaksh TL. A-85380 and epibatidine each interact with disparate spinal nicotinic receptor subtypes to achieve analgesia and nociception. J Pharmacol Exp Ther. 2001;297:230–239
  66. Khan IM, Taylor P, Yaksh TL. Cardiovascular and behavioral responses to nicotinic agents administered intrathecally. J Pharmacol Exp Ther. 1994;270:150–158
  67. Khiroug SS, Harkness PC, Lamb PW, Sudweeks SN, Khiroug L, Millar NS, et al. Rat nicotinic ACh receptor α7 and β2 subunits co-assemble to form functional heteromeric nicotinic receptor channels. J Physiol. 2002;540:425–434
  68. Kiyosawa A, Katsurabayashi S, Akaike N, Pang ZP, Akaike N. Nicotine facilitates glycine release in the rat spinal dorsal horn. J Physiol. 2001;536:101–110
  69. Kuryatov A, Luo J, Cooper J, Lindstrom J. Nicotine acts as a pharmacological chaperone to up-regulate human α4β2 acetylcholine receptors. Mol Pharmacol. 2005;68:1839–1851
  70. Kuryatov A, Onksen J, Lindstrom J. Roles of accessory subunits in α4β2∗ nicotinic receptors. Mol Pharmacol. 2008;74:132–143
  71. Lansdell SJ, Collins T, Yabe A, Gee VJ, Gibb AJ, Millar NS. Host-cell specific effects of the nicotinic acetylcholine receptor chaperone RIC-3 revealed by a comparison of human and Drosophila RIC-3 homologues. J Neurochem. 2008;105:1573–1581
  72. Lansdell SJ, Gee VJ, Harkness PC, Doward AI, Baker ER, Gibb AJ, et al. RIC-3 enhances functional expression of multiple nicotinic acetylcholine receptor subtypes in mammalian cells. Mol Pharmacol. 2005;68:1431–1438
  73. Lawand NB, Lu Y, Westlund KN. Nicotinic cholinergic receptors: potential targets for inflammatory pain relief. Pain. 1999;80:291–299
  74. Lena C, Changeux JP. Role of Ca2+ ions in nicotinic facilitation of GABA release in mouse thalamus. J Neurosci. 1997;17:576–585
  75. Lester HA, Xiao C, Srinivasan R, Son CD, Miwa J, Pantoja R, et al. Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery. AAPS J. 2009;11:167–177
  76. Liu QS, Berg DK. Extracellular calcium regulates responses of both α3- and α7-containing nicotinic receptors on chick ciliary ganglion neurons. J Neurophysiol. 1999;82:1124–1132
  77. Macor JE, Gurley D, Lanthorn T, Loch J, Mack RA, Mullen G, et al. The 5-HT3 antagonist tropisetron (ICS 205–930) is a potent and selective alpha7 nicotinic receptor partial agonist. Bioorg Med Chem Lett. 2001;11:319–321
  78. Mantyh PW, Rogers SD, Honore P, Allen BJ, Ghilardi JR, Li J, et al. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science. 1997;278:275–279
  79. Mao D, Yasuda RP, Fan H, Wolfe BB, Kellar KJ. Heterogeneity of nicotinic cholinergic receptors in rat superior cervical and nodose Ganglia. Mol Pharmacol. 2006;70:1693–1699
  80. Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Lena C, Le Novere N, de Kerchove d’Exaerde A, et al. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature. 1999;398:805–810
  81. Mazurov A, Hauser T, Miller CH. Selective α7 nicotinic acetylcholine receptor ligands. Curr Med Chem. 2006;13:1567–1584
  82. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 1995;269:1692–1696
  83. Medhurst SJ, Hatcher JP, Hille CJ, Bingham S, Clayton NM, Billinton A, et al. Activation of the α7-nicotinic acetylcholine receptor reverses complete freund adjuvant-induced mechanical hyperalgesia in the rat via a central site of action. J Pain. 2008;9:580–587
  84. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol. 2006;70:801–805
  85. Millar NS, Gotti C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology. 2009;56:237–246
  86. Mulle C, Lena C, Changeux JP. Potentiation of nicotinic receptor response by external calcium in rat central neurons. Neuron. 1992;8:937–945
  87. Nelson ME, Kuryatov A, Choi CH, Zhou Y, Lindstrom J. Alternate stoichiometries of α4β2 nicotinic acetylcholine receptors. Mol Pharmacol. 2003;63:332–341
  88. Nichols ML, Allen BJ, Rogers SD, Ghilardi JR, Honore P, Luger NM, et al. Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science. 1999;286:1558–1561
  89. Orr-Urtreger A, Goldner FM, Saeki M, Lorenzo I, Goldberg L, De Biasi M, et al. Mice deficient in the α7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci. 1997;17:9165–9171
  90. Papke RL, Porter Papke JK, Rose GM. Activity of alpha7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes. Bioorg Med Chem Lett. 2004;14:1849–1853
  91. Parrish WR, Rosas-Ballina M, Gallowitsch-Puerta M, Ochani M, Ochani K, Yang LH, et al. Modulation of TNF release by choline requires α7 subunit nicotinic acetylcholine receptor-mediated signaling. Mol Med. 2008;14:567–574
  92. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, et al. SSR180711, a novel selective α7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology. 2007;32:17–34
  93. Quick MW, Lester RA. Desensitization of neuronal nicotinic receptors. J Neurobiol. 2002;53:457–478
  94. Ramirez-Latorre J, Yu CR, Qu X, Perin F, Karlin A, Role L. Functional contributions of α5 subunit to neuronal acetylcholine receptor channels. Nature. 1996;380:347–351
  95. Razani-Boroujerdi S, Boyd RT, Davila-Garcia MI, Nandi JS, Mishra NC, Singh SP, et al. T cells express α7-nicotinic acetylcholine receptor subunits that require a functional TCR and leukocyte-specific protein tyrosine kinase for nicotine-induced Ca2+ response. J Immunol. 2007;179:2889–2898
  96. Rodrigues-Pinguet NO, Pinguet TJ, Figl A, Lester HA, Cohen BN. Mutations linked to autosomal dominant nocturnal frontal lobe epilepsy affect allosteric Ca2+ activation of the α4β2 nicotinic acetylcholine receptor. Mol Pharmacol. 2005;68:487–501
  97. Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential. ChemMedChem. 2007;2:746–767
  98. Roth AL, Berg DK. Large clusters of α7-containing nicotinic acetylcholine receptors on chick spinal cord neurons. J Comp Neurol. 2003;465:195–204
  99. Rowbotham MC, Duan WR, Thomas J, Nothaft W, Backonja MM. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. Pain. 2009;146:245–252
  100. Rueter LE, Donnelly-Roberts DL, Curzon P, Briggs CA, Anderson DJ, Bitner RS. A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor. CNS Drug Rev. 2006;12:100–112
  101. Rueter LE, Kohlhaas KL, Curzon P, Surowy CS, Meyer MD. Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain. Pain. 2003;103:269–276
  102. Sarter M, Parikh V, Howe WM. Phasic acetylcholine release and the volume transmission hypothesis: time to move on. Nat Rev Neurosci. 2009;10:383–390
  103. Skoubis PD, Hradil V, Chin CL, Luo Y, Fox GB, McGaraughty S. Mapping brain activity following administration of a nicotinic acetylcholine receptor agonist, ABT-594, using functional magnetic resonance imaging in awake rats. Neuroscience. 2006;137:583–591
  104. Spath M, Stratz T, Neeck G, Kotter I, Hammel B, Amberger CC, et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol. 2004;33:267–270
  105. Springer SK, Woodin KS, Berry V, Boezio AA, Cao L, Clarkin K, et al. Synthesis and activity of substituted carbamates as potentiators of the α4β2 nicotinic acetylcholine receptor. Bioorg Med Chem Lett. 2008;18:5643–5647
  106. Stauderman KA, Mahaffy LS, Akong M, Velicelebi G, Chavez-Noriega LE, Crona JH, et al. Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations α2β4, α3β4 and α4β4 stably expressed in HEK293 cells. J Pharmacol Exp Ther. 1998;284:777–789
  107. Strick PL, Dum RP, Fiez JA. Cerebellum and nonmotor function. Annu Rev Neurosci. 2009;32:413–434
  108. Takeda D, Nakatsuka T, Gu JG, Yoshida M. The activation of nicotinic acetylcholine receptors enhances the inhibitory synaptic transmission in the deep dorsal horn neurons of the adult rat spinal cord. Mol Pain. 2007;3:26
  109. Takeda D, Nakatsuka T, Papke R, Gu JG. Modulation of inhibitory synaptic activity by a non-α4β2, non-α7 subtype of nicotinic receptors in the substantia gelatinosa of adult rat spinal cord. Pain. 2003;101:13–23
  110. Tapia L, Kuryatov A, Lindstrom J. Ca2+ permeability of the (α4)3(β2)2 stoichiometry greatly exceeds that of (α4)2(β2)3 human acetylcholine receptors. Mol Pharmacol. 2007;71:769–776
  111. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, et al. Nicotine activation of α4∗ receptors: sufficient for reward, tolerance, and sensitization. Science. 2004;306:1029–1032
  112. Tolk J, Kohnen R, Muller W. Intravenous treatment of fibromyalgia with the 5-HT3 receptor antagonist tropisetron in a rheumatological practice. Scand J Rheumatol. 2004;119:72–75
  113. Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron. 2007;55:377–391
  114. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest. 2007;117:289–296
  115. Turner JR, Kellar KJ. Nicotinic cholinergic receptors in the rat cerebellum: multiple heteromeric subtypes. J Neurosci. 2005;25:9258–9265
  116. Varanda WA, Aracava Y, Sherby SM, VanMeter WG, Eldefrawi ME, Albuquerque EX. The acetylcholine receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist. Mol Pharmacol. 1985;28:128–137
  117. Vernallis AB, Conroy WG, Berg DK. Neurons assemble acetylcholine receptors with as many as three kinds of subunits while maintaining subunit segregation among receptor subtypes. Neuron. 1993;10:451–464
  118. Vincler M. Neuronal nicotinic receptors as targets for novel analgesics. Expert Opin Investig Drugs. 2005;14:1191–1198
  119. Vincler M, Eisenach JC. Plasticity of spinal nicotinic acetylcholine receptors following spinal nerve ligation. Neurosci Res. 2004;48:139–145
  120. Vincler MA, Eisenach JC. Knock down of the alpha 5 nicotinic acetylcholine receptor in spinal nerve-ligated rats alleviates mechanical allodynia. Pharmacol Biochem Behav. 2005;80:135–143
  121. Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J, et al. Distribution of α2, α3, α4, and β2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J Comp Neurol. 1989;284:314–335
  122. Wang F, Gerzanich V, Wells GB, Anand R, Peng X, Keyser K, et al. Assembly of human neuronal nicotinic receptor α5 subunits with α3, β2, and β4 subunits. J Biol Chem. 1996;271:17656–17665
  123. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature. 2003;421:384–388
  124. Wang Y, Su DM, Wang RH, Liu Y, Wang H. Antinociceptive effects of choline against acute and inflammatory pain. Neuroscience. 2005;132:49–56
  125. Williams ME, Burton B, Urrutia A, Shcherbatko A, Chavez-Noriega LE, Cohen CJ, et al. Ric-3 promotes functional expression of the nicotinic acetylcholine receptor α7 subunit in mammalian cells. J Biol Chem. 2005;280:1257–1263
  126. Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, et al. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure–activity relationship. J Med Chem. 2006;49:4425–4436
  127. Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J Neurosci. 2003;23:3176–3185
  128. Yaksh TL, Ozaki G, McCumber D, Rathbun M, Svensson C, Malkmus S, et al. An automated flinch detecting system for use in the formalin nociceptive bioassay. J Appl Physiol. 2001;90:2386–2402
  129. Young T, Wittenauer S, McIntosh JM, Vincler M. Spinal α3β2∗ nicotinic acetylcholine receptors tonically inhibit the transmission of nociceptive mechanical stimuli. Brain Res. 2008;1229:118–124

PII: S0304-3959(10)00029-1

doi: 10.1016/j.pain.2010.01.007

PAIN
Volume 149, Issue 1 , Pages 33-49 , April 2010

Article Tools

* Image Usage & Resolution